# Expanded Access Program of Ponatinib

> **NCT01592136** · — · APPROVED_FOR_MARKETING · sponsor: **Ariad Pharmaceuticals**

## Conditions studied

- Chronic Myeloid Leukemia (CML)
- Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)

## Interventions

- **DRUG:** ponatinib

## Key facts

- **NCT ID:** NCT01592136
- **Lead sponsor:** Ariad Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** APPROVED_FOR_MARKETING
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2018-02-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01592136

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01592136, "Expanded Access Program of Ponatinib". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT01592136. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*